White label – Pompe disease - ClinicalTrials.eu

Study on Darolutamide and Androgen Deprivation Therapy for Men with Metastatic Hormone-Sensitive Prostate Cancer

Not recruiting

3 1 1
Investigated Diseases:
- Prostate cancer metastatic
Investigated Drugs:
- Darolutamide
Study of ISIS 678354 for Patients with Severe Hypertriglyceridemia

Not recruiting

3 1 1
Investigated Drugs:
- Isis 678354 Sodium Salt
+13
Study of Capivasertib with CDK4/6 Inhibitors and Fulvestrant for Patients with Advanced HR+/HER2- Breast Cancer

Not recruiting

3 1 1 1
Investigated Diseases:
- Hormone receptor positive HER2 negative breast cancer
Investigated Drugs:
+2
Study to Evaluate the Effectiveness of Spesolimab for Patients with Moderate to Severe Hidradenitis Suppurativa

Not recruiting

4 1
Investigated Diseases:
- Hidradenitis
Investigated Drugs:
- Spesolimab
+11
Study on Detecting Early Barrett’s Esophagus Using Bevacizumab-800CW and Cetuximab-800CW for Patients with Barrett’s Esophagus

Not recruiting

2 1 1 1
Investigated Diseases:
- Barrett’s oesophagus
Investigated Drugs:
- Bevacizumab
- Cetuximab
Study on the Effects of Obefazimod for Patients with Moderate to Severe Ulcerative Colitis

Not recruiting

3 1
Investigated Drugs:
- Obefazimod
+8
Study on the Effects of Obefazimod for Patients with Moderate to Severe Ulcerative Colitis

Not recruiting

3 1
Investigated Diseases:
- Colitis ulcerative
Investigated Drugs:
- Obefazimod
+7
Continued Darolutamide Treatment for Cancer Patients from Previous Bayer Studies

Not recruiting

3 1 1
Investigated Drugs:
- Darolutamide
+11
Study on the Effects of Tasipimidine for Patients with Insomnia Disorder

Not recruiting

2 1
Investigated Diseases:
- Insomnia
Investigated Drugs:
- Tasipimidine
Study of BMS-986408 Alone or with Nivolumab and Ipilimumab for Patients with Advanced Solid Tumors

Not recruiting

2 1 1 1
Investigated Diseases:
- Neoplasm
Investigated Drugs:

Full Name *

e-Mail *

Country Prefix *

Phone Number *

Nationality *

Gender *

Check all consents

Check all consents

I accept the Terms and Conditions and Privacy Policy *

*I accept the Terms and Conditions and Privacy Policy

I consent to receiving commercial information from the Service Operator *

*I consent to receiving commercial information from the Service Operator

I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes *

*I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes

We use cookies